最近关于对葡萄糖敏感的康卡纳瓦林 A 基智能水凝的见解,用于控制胰岛素输送
Maria Bercea1, Alexandra Lupu1
1"Petru Poni" Institute of Macromolecular Chemistry, 41-A Grigore Ghica Voda Alley, 700487 Iasi, Romania.
Gels (Basel, Switzerland)
|April 26, 2024
概括
研究人员正在开发用于糖尿病管理的智能生物材料. 这些材料使用康卡纳瓦林A (Con A) 蛋白来制造对葡萄糖敏感的水凝,用于精确的胰岛素输送和生物传感.
科学领域:
- 生物材料科学 生物材料科学
- 生物化学 生物化学
- 纳米技术 纳米技术
背景情况:
- 开发对葡萄糖敏感的生物材料对于控制血糖水平和实现自我调节的胰岛素输送至关重要.
- 随着葡萄糖度的变化而改变体积的水凝对血糖监测和量身定制的胰岛素剂量有希望.
- 创建基于可逆结合葡萄糖的传感器仍然是一个重大挑战.
研究的目的:
- 对康卡纳瓦林A (Con A) 在开发用于糖尿病诊断和治疗的智能材料中的使用进行审查.
- 为了突出Con A作为葡萄糖反应系统的自然受体的潜力.
- 探索基于Con A的水凝,微凝,纳米颗粒和用于生物传感和药物输送的膜.
主要方法:
- 基于康卡纳瓦林A (Con A) 的葡萄糖反应材料的文献综述.
- 对Con A的特性进行分析,包括其对葡萄糖和曼诺糖的特定结合亲和力.
- 检查用于糖尿病管理的水凝,微凝,纳米颗粒和薄膜中的应用.
主要成果:
- 剑豆植物中的蛋白质Concanavalin A (Con A) 对葡萄糖和曼诺酸具有很高的亲和力,因此适用于对葡萄糖敏感的材料.
- Con A已经成功地被纳入各种智能材料,如水凝,微凝,纳米粒子和薄膜.
- 这些基于ConA的材料显示出对葡萄糖生物传感和向胰岛素输送系统的潜力.
结论:
- 康卡纳瓦林A (Con A) 是一种有价值的自然受体,用于制造先进的对葡萄糖敏感的生物材料.
- 基于ConA的材料为改善糖尿病诊断和治疗提供了有希望的途径.
- 未来的研究可能会扩展到用于癌症治疗的葡萄糖衍生治疗药.
相关概念视频
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Insulin Formulations: Types and Delivery
191
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
191
Insulin: Biosynthesis, Chemistry, and Preparation
374
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
374


